Welcome to our dedicated page for Neumora Therapeutics SEC filings (Ticker: NMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neumora Therapeutics, Inc. (NMRA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biopharmaceutical company, Neumora uses current reports on Form 8-K and other filings to communicate material information about its financial condition, capital structure and key pipeline events.
In recent 8-K filings, Neumora has reported quarterly financial results, including details on research and development and general and administrative expenses, net loss and cash, cash equivalents and marketable securities. These filings also reference the company’s expectation that its available capital will fund its operating plan into 2027, based on the specific reporting dates. Other 8-Ks describe business updates such as the initiation of a Phase 1 SAD/MAD study of NMRA-898, a positive preclinical data announcement for NMRA-215, and the associated press releases furnished or filed as exhibits.
Neumora has also filed an 8-K describing a conversion under its Loan and Security Agreement with K2 HealthVentures LLC, in which a portion of the outstanding term loan principal was converted into shares of common stock. This filing outlines the conversion terms, the number of shares issued and the reliance on a registration exemption under the Securities Act of 1933.
On Stock Titan, Neumora’s SEC filings are updated as they appear on EDGAR, and AI-powered summaries help explain the key points in plain language. Users can review current reports on Form 8-K for material events, track changes related to financing arrangements, and connect these disclosures with the company’s broader clinical and business narrative. This page is a resource for understanding how Neumora reports its financial results, capital transactions and significant pipeline milestones to regulators and investors.
Neumora Therapeutics furnished a corporate presentation for use at the Guggenheim Emerging Outlook: Biotech Summit, highlighting Phase 1b data for NMRA-511 in agitation associated with Alzheimer’s disease. The randomized, double-blind study enrolled 40 patients on NMRA-511 and 40 on placebo over eight weeks, plus a small healthy-elderly cohort.
In a pre-specified elevated anxiety subgroup, NMRA-511 showed Cohen’s d effect sizes of 0.51–0.64 on the CMAI agitation scale, up to 0.78 on CGI-S agitation, and 0.42–0.46 on the NPI agitation/aggression domain, with nominal p-values down to <0.05. Treatment-emergent adverse events were generally mild to moderate, discontinuations due to side effects were 2.5%, and one serious adverse event resolved fully. The company notes potential for higher dosing and future studies that enrich for patients with elevated anxiety.
Neumora Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings with investors and analysts at the 44th Annual J.P. Morgan Healthcare Conference. The presentation, dated January 2026, is provided as Exhibit 99.1 to this report and is incorporated into the report by reference.
The company notes that the presentation and related information are being furnished, not filed, which means they are not subject to certain liability provisions under federal securities laws and will not automatically be incorporated into other SEC documents.
Neumora Therapeutics, Inc. reported that its Chief Financial Officer and Principal Accounting Officer, Michael Lee Milligan, received a grant of a stock option covering 350,000 shares of common stock on January 8, 2026. The option has an exercise price of $2.33 per share and is held directly. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. reported a Form 4 transaction for officer Daljit Singh Aurora, its Chief Operating and Development Officer. On January 8, 2026, Aurora received a stock option to buy 750,000 shares of common stock at an exercise price of $2.33 per share, with no cost reported for the option itself.
All 750,000 derivative securities are shown as beneficially owned directly after the grant. The option vests over four years: 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the option is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. officer Jason Duncan received a grant of stock options covering 750,000 shares of common stock on January 8, 2026. These options give him the right to buy those shares at an exercise price of $2.33 per share. The grant was reported as a direct beneficial ownership position, with 750,000 derivative securities held after the transaction.
According to the vesting terms, 25% of the option shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years. This structure means the option becomes fully vested and exercisable on the fourth anniversary of the vesting commencement date, aligning the officer’s potential equity ownership with longer-term service to the company.
Neumora Therapeutics, Inc.Joshua PintoJanuary 8, 2026, he was granted an option to purchase 1,200,000 shares of common stock at an exercise price of $2.33 per share. According to the vesting terms, 25% of the shares vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.
Neumora Therapeutics, Inc. reported that Chief Executive Officer and Chairman of the Board Paul L. Berns received a grant of stock options on January 8, 2026. The Form 4 shows an award of 1,650,000 stock options, each with an exercise price of
According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of January 8, 2026, and the remaining shares vest in equal monthly installments so that the entire grant is fully vested and exercisable on the fourth anniversary of that date.
Neumora Therapeutics, Inc. reported that its lender K2 HealthVentures exercised a conversion right under an existing Loan and Security Agreement. K2 HealthVentures converted $2.5 million of term loan principal into common stock at a price of $0.8774 per share, as allowed under the agreement that permits conversion of up to $12.5 million of principal. On November 20, 2025, Neumora issued 2,849,327 shares of common stock to K2 HealthVentures Equity Trust LLC in connection with this conversion. The shares were issued as a private offering relying on the registration exemption in Section 4(a)(2) of the Securities Act of 1933.
Neumora Therapeutics (NMRA) officer Daljit Singh Aurora reported an open-market sale of 114,703 shares of common stock on 11/11/2025 at a weighted average price of $2.6767. The sale was made under a Rule 10b5-1 trading plan adopted on April 22, 2024, and the sold shares were held by the Aurora Family Trust. Following the transaction, Aurora reported 88,935 shares held directly and 0 shares held indirectly.
Neumora Therapeutics reported a Q3 2025 net loss of $56.8 million, with nine‑month net loss at $177.5 million. Operating expenses fell year over year as research and development declined to $40.5 million from $60.6 million, and general and administrative to $12.2 million from $16.0 million. The company recorded $5.0 million of acquired in‑process R&D tied to its Vanderbilt M4 program.
Cash, cash equivalents and marketable securities totaled $171.5 million as of September 30, 2025. Neumora believes this will fund operations for at least the next 12 months. In May, it drew $20.0 million from a term loan facility with K2 HealthVentures (up to $125.0 million across tranches) at a minimum rate of 10.45%, and subsequently borrowed an additional $40.0 million after quarter‑end.
The pipeline includes a Phase 3 program for navacaprant in major depressive disorder and a Phase 1b study for NMRA‑511 in agitation due to Alzheimer’s disease, with early‑stage M4 PAM candidates advancing. Shares outstanding were 167,089,114 as of November 1, 2025.